Salmeterol/fluticasone propionate in a Single Inhaler Device versus theophylline + fluticasone propionate in patients with COPD

Pulmonary Pharmacology and Therapeutics

Volumn 17, Issue 3, 2004, Pages 141-145

  Cazzola, Mario ^a   Noschese, Paolo ^a   Centanni, Stefano ^b   Santus, Pierachile ^b   Di Marco, Fabiano ^b   Spicuzza, Lucia ^c   Di Maria, Giuseppe Ugo ^c  

^a CARDARELLI HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

Author keywords

Chronic obstructive pulmonary disease; Combination therapy; Fluticasone propionate; Salmeterol; Theophylline

Indexed keywords

DISKUS; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; SALBUTAMOL; THEOPHYLLINE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; HUMAN; INHALER; LUNG FUNCTION; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOMATOLOGY; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

AGED; ALBUTEROL; ANDROSTADIENES; BRONCHODILATOR AGENTS; DRUG COMBINATIONS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING; THEOPHYLLINE;

EID: 1942518243     PISSN: 10945539     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pupt.2004.01.004     Document Type: Article

References (17)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Workshop Report. Bethesda, National Heart, Lung and Blood Institute; April 2001. Update of the Management Sections, GOLD website ( www.goldcopd.com ). Date updated; July 2003.
2. Rudolf M. The reality of drug use in COPD: the European perspective. Chest. 117:(Suppl. 2):2000;29S-32S.
3. 2- agonists and theophylline in stable chronic obstructive pulmonary disease. Thorax. 54:1999;730-736.
4. Kerstjens H.A.M. Clinical evidence: stable chronic obstructive pulmonary disease. BMJ. 319:1999;495-500.
5. Soriano J.B., Vestbo J., Pride N.B., et al. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J. 20:2002;819-825.
6. Cazzola M., Di Lorenzo G., Di Perna F., Caloleraro F., Testi R., Centamni S., Chang C.N., Yates J., Fisher T., Shah T. Additive effects of salmeterol and fluticasone or theophylline in COPD. Chest. 118:2000;1576-1581.
7. Mahler D.A., Wire P., Horstman D., et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 166:2002;1084-1091.
8. Calverley P., Pauwels R., Vestbo J., Jones P., Priole N., Sulsvik A., Anderson J., Maolem C. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 361:2003;449-456.
9. Dal Negro R.W., Pomari C., Tognella S., Micheletto C. Salmeterol and fluticasone 50 μg/250 μg bid in combination provides a better long-term control than salmeterol 50 μg bid alone and placebo in COPD patients already treated with theophylline. Pulm Pharmacol Ther. 16:2003;241-246.
10. Hanania N.A., Darken P., Horstman D., Reismer C., Lee B., Davis S., Shah T. The efficacy and safety of fluticasone propionate (250 μg)/salmeterol (50 μg) combined in the Diskus inhaler for the treatment of COPD. Chest. 124:2003;834-843.
11. American Thoracic Society. Standardization of spirometry, 1987 update. Am Rev Respir Dis. 136:1987;1285-1298.
12. Mahler D., Guyatt G.H., Jones P.W. Clinical measurement of dyspnea. Mahler D. Dyspnea. 1998;149-198 Marcel Dekker, New York.
13. Noseda A., Schmerber J., Prigogine T., Yermault J.C. How do patients with either asthma or COPD perceive acute bronchodilation? Eur Respir J. 6:1993;636-644.
14. Foglio K., Bianchi L., Bruletti G., et al. Long-term effectiveness of pulmonary rehabilitation in patients with chronic airway obstruction. Eur Respir J. 13:1999;125-132.
15. Janson C., Chinn S., Jarvis D., Burmey P. Physician-diagnosed asthma and drug utilization in the European Community Respiratory Health Survey. Eur Respir J. 10:1997;1795-1802.
16. Johnston I., Jenkinson D. Are theophyllines being prescribed effectively and safely in general practice? Br J Clin Pract. 49:1995;16-18.
17. Mahler D.A. How should health-related quality of life be assessed in patients with COPD? Chest. 117:(2):2000;54S-57S.